University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will ...

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition ...

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition is advancing a robust pipeline of PRINTed therapeutics ...

Addition joins a growing list of launches this year, following in the footsteps of startups like Crystalys Therapeutics and ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene ...

The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

Who needs big guns and even bigger explosions? These top-rated stealth games let you save the world using quiet precision. My PCMag career began in 2013 as an intern. Now, I'm a senior writer, using ...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying ...